Headlines about Oramed Pharmaceuticals (NASDAQ:ORMP) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Oramed Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 44.4019086324316 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of research firms have weighed in on ORMP. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Oramed Pharmaceuticals in a report on Thursday, October 5th. ValuEngine raised shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, B. Riley reissued a “buy” rating and set a $20.00 target price on shares of Oramed Pharmaceuticals in a report on Tuesday.

Shares of Oramed Pharmaceuticals (ORMP) opened at $8.36 on Friday. Oramed Pharmaceuticals has a 12 month low of $5.85 and a 12 month high of $11.34. The company has a market cap of $120.46, a price-to-earnings ratio of -10.86 and a beta of 1.09.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings data on Wednesday, November 29th. The biotechnology company reported ($0.20) EPS for the quarter. Oramed Pharmaceuticals had a negative net margin of 169.17% and a negative return on equity of 49.94%. equities analysts predict that Oramed Pharmaceuticals will post -1.3 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://theolympiareport.com/2018/01/19/oramed-pharmaceuticals-ormp-given-daily-news-sentiment-rating-of-0-14.html.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Insider Buying and Selling by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.